BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Harvard Business School
US Army
Colorcon
Farmers Insurance
Daiichi Sankyo
Citi
Teva
QuintilesIMS

Generated: January 16, 2018

DrugPatentWatch Database Preview

Sunovion Pharms Inc Company Profile

« Back to Dashboard

Summary for Sunovion Pharms Inc
International Patents:496
US Patents:30
Tradenames:7
Ingredients:7
NDAs:7

Drugs and US Patents for Sunovion Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-003 Dec 7, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-002 Oct 28, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sunovion Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SUNOVION PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg ➤ Subscribe 10/28/2014
➤ Subscribe Tablets 1 mg, 2 mg and 3 mg ➤ Subscribe 12/15/2008

Non-Orange Book US Patents for Sunovion Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets ➤ Subscribe
8,182,791 Formulations for use in inhaler devices ➤ Subscribe
5,780,632 Imide derivatives and their production and use ➤ Subscribe
7,541,022 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
8,288,532 Asymmetric catalytic reduction of oxcarbazepine ➤ Subscribe
9,566,239 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
9,351,928 Method of making particles for use in a pharmaceutical composition ➤ Subscribe
8,871,274 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
8,932,635 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation ➤ Subscribe
9,585,839 Particles for use in a pharmaceutical composition ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Sunovion Pharms Inc Drugs

Supplementary Protection Certificates for Sunovion Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1183240/01 Switzerland ➤ Subscribe FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
C/GB09/047 United Kingdom ➤ Subscribe PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTERED: UK EU/1/09/514/001 20090421; UK EU/1/09/514/002 20090421; UK EU/1/09/514/003 20090421; UK EU/1/09/514/004 20090421; UK EU/1/09/514/005 20090421; UK EU/1/09/514/006 20090421; UK EU/1/09/514/019 20090421; UK EU/1/09/514/020 20090421; UK EU/1/09/514/013 20090421; UK EU/1/09/514/014 20090421; UK EU/1/09/514/015 20090421; UK EU/1/09/514/016 20090421; UK EU/1/09/514/017 20090421; UK EU/1/09/514/018 20090421; UK EU/1/09/514/007 20090421; UK EU/1/09/514/008 20090421; UK EU/1/09/514/009 20090421; UK EU/1/09/514/010 20090421; UK EU/1/09/514/011 20090421; UK EU/1/09/514/012 20090421
7/2010 Austria ➤ Subscribe PRODUCT NAME: INDACATEROL UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON
1 5024-2014 Slovakia ➤ Subscribe PRODUCT NAME: LURASIDON; REGISTRATION NO/DATE: EU/14/913/001 - EU/14/913/021 20140327
0583 Netherlands ➤ Subscribe PRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE AFGELEIDEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
0140030 00118 Estonia ➤ Subscribe PRODUCT NAME: LURASIDOON;REG NO/DATE: K(2014)2046 (LOPLIK) 27.03.2014
651 Luxembourg ➤ Subscribe 91651, EXPIRES: 20241130
2014000092 Germany ➤ Subscribe PRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321
13/014 Ireland ➤ Subscribe PRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
00690 Netherlands ➤ Subscribe PRODUCT NAME: LURASIDON, OPTIONEEL IN DE VORM VAN ZIJN VRIJE BASE OF FARMACEUTISCH ACCEPTABELE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/14/913 20140321
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Argus Health
Boehringer Ingelheim
Fish and Richardson
Julphar
Teva
McKinsey
Federal Trade Commission
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot